폐경 전 유방암 환자의 치료 전·후 골밀도 변화 분석
An Analysis of BMD Changes With Preoperative and Postoperative Premenopausal Breast Cancer Patient
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
유방암 환자의 외과적 수술과 방사선 및 화학적 치료 전·후의 골밀도 수치를 비교함으로써 암 치료에 의한 골소실 문제의 심각성을 도출하여 고 위험군선별 및 골다공증예방을 위한 기초자료를 제공하고자 하였다. 2007년 3월부터 2013년 9월까지 유방암으로 진단을 받고 수술 및 치료를 받은 후 골밀도 검사를 시행한 환자 254명을 대상으로 하였다. 이중 폐경에 이르렀거나 자궁적출술을 받아 폐경된 84명을 제외한 171명을 최종 분석의 대상으로 하였다. 방사선흡수법에 의한 골밀도 영상(요추부위와 대퇴골부위)에서 치료 전·후 측정된 골밀도 수치를 분석하였다. 치료 전·후의 전체적인 골밀도 변화량과 치료유형별 변화량을 비교하였으며, 환자의 결혼 유무, 자녀수, 수유유무, 초경나이, 유방암 치료형태 등을 변수로 하여 세부적인 차이점 및 연관성을 분석하였다. 측정된 자료는 SPSS for Windows Program(Version 18.0)을 사용하여 통계 분석하였다. 요추에서는 치료 후 평균 7.1% 감소하였고, 대퇴골에서는 평균 3.1% 감소하였으며, 통계적으로 매우 유의한 차이를 보였다(p<.01). 또한 화학적 치료를 시행한 환자군의 대퇴골 부위에서 치료 및 수술 후 0.067g/cm2의 상대적으로 큰 골밀도 수치의 감소량을 보였으며 통계적으로 유의하였다(p<.05). 그 외 결혼 유무, 자녀수, 수유 유무, 초경 나이 등에 따라서는 감소량의 차이가 있었지만 통계적 수준에서 유의성은 없었다. 폐경 전 유방암 환자의 치료 후 골밀도 수치 감소를 보임에 따라 감소량이 상대적으로 큰 환자를 고 위험군에 포함시켜야 할 것이며, 이를 토대로 적극적인 예방 정책이 필요하리라 사료된다.
Abstract
The purpose of this study is to provide basic data of comparing BMD(bone mineral density) value of preoperative breast cancer patient and postoperative breast cancer patient due to bone loss with radiation/chemical therapy. The participants consisted of 254 breast cancer patients with BMD after having surgery and treatment from March 2007 to September 2013. Except for 84 patients with menopause or hysterectomy and we have analysed 171 patients. The BMD value(lumbar spine and femur) of before and after treatment from PACS by dure-energy X-ray absorptiometry was analyzed. First, we found variation of entire BMD and BMD according to treatment type, and analyzed detailed correlation by using marital status, number of children, presence of feeding, age of menarche, breast cancer therapy types as variable. Data was analyzed by using SPSS for Windows Program(version 18.0). BMD was decreased 7.1% in lumbar spine, 3.1% in femur respectively(p<.01). Also there is relatively high decrement(0.067g/cm2) in group who had just chemotherapy in femur(p<.05). There is decrement depend on marital status, number of children, presence of feeding, age of menarche, breast cancer therapy types but there was no statistical significance. The results show that BMD was decreased after treatment in premenopausal breast cancer patient, patient who had relatively high decrement need to be included high-risk group. As a result, aggressive prevention policy would be necessary.
참고문헌 (25)
- "Breast cancer fact sheet", Korean Breast Cancer Society, ~ (2006)
- "Cancer Facts and Figures" (2010)[URL]
- Bruning PF, "Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer", Br J Cancer, 61, pp.308~310 (1990)
- Waltman NL, "Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors.", J Nurs Scholarsh, 35(4), pp.333~338 (2003)
- Kanis JA, "A high incidence of vertebral fracture in women with breast cancer", Br J Cancer, 79, pp.1178~ (1999)
- Bethesda, "What Breast Cancer Survivors Need to Know About Osteoporosis", National Institutes of Health, 2, pp.8~18 (2012)
- Korean Society of Bone Metabolism, "Physician’guide for diagnosis and treatment of osteoporosis" (2011), Minkum
- Michaud LB, "Cancer-treatment-induced bone loss, part 1", Am J Health Syst Pharm, 63, pp.419~430 (2006)
- Hillner BE, "American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer", J Clin Oncol, 21, pp.4042~4057 (2003)
- Gralow JR, "NCCN task force report: bone health in cancer care", J Natl ComprCanc Netw, 3, pp.31~32 (2009)
- Lønning PE, "Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer", J Clin Oncol, 23, pp.5126~5137 (2005)
- Pandya N, "Toxicity of aromatase inhibitors", Semin Oncol, 33(6), pp.688~695 (2006)
- Vehmanen L, "Tamoxifen treatment after adjuvunt chemotherapy pausal patients depending on menstrual status", Journal of Clinical Oncolohy, 24, pp.675~ (2006)
- Finkelstein JS, "Cecil text- book of medicine", pp.1366~1373 (2000), W.B. Saunders
- Chen Z, "Fracture risk among breast cancer survivors: results from the women’health initiative observational study", Arch Intern Med, 165, pp.552~558 (2005)
- Kanis JA, "A high ncidence of vertebral fracture in women with breast cancer", Br J Cancer, 79, pp.1179~1180 (1999)
- Williams HJ, "The effect of X-rays on bone", Eur Radiol, 16, pp.619~633 (2006)
- van der Klift M, "Rotterdam Study, Bone mineral density and the risk of breast cancer:the Rotterdam Study", Bone, 32, pp.211~216 (2003)
- Shapiro CL, "Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer", J Clin Oncol, 19, pp.3306~3311 (2001)
- Kim SH, "Low bone density in breastcancer survivors in Korea: prevalence, risk factors and associations withhealth-related quality of life", Eur J Oncol Nurs, 17, pp.196~203 (2013)
- Nyaruba MM, "Bone fragility induced by X-ray irradiation in relation to cortical bone mineral content", Acta Radiol, 39, pp.43~46 (1998)
- McKay HA, "Lifestyle determinants of bone mineral: a comparison between prepubertal Asian-and Caucasian-Canadian boys and girls", Calcified Tissue International, 66, pp.320~324 (2000)
- 임화재, "폐경전 성인직장여성의 골밀도와 생리적 특성 및 생활습관과의 관련성", 한국식품영양과학회지, 33(2), pp.339~348 (2004), 한국식품영양과학회
- Cure-Cure C, "Bone-mass peak in multiparity and reduced risk of bone-fractures in menopause", International Journal of Gynaecology and Obstetrics, 76, pp.285~291 (2002)
- Hadji P1, "Practical guidance for the management of aromatase inhibitor-associated bone loss", Ann Oncol, 19, pp.1407~1416 (2008)